Navigation Links
Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis 2016-2017: IPF Pipeline is Very Strong with a Total of 97 Drug Candidates - Research and Markets
Date:3/24/2017

DUBLIN, Mar. 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016" report to their offering.

The IPF pipeline is very strong with a total of 97 drug candidates. Pharma giant such as Asahi Kasei Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the development of the IPF therapeutics. The IPF pipeline comprised of 97 product candidates, of which one is in Phase III stage, 15 are in Phase II stage, 12 are in Phase I stage, 39 are in Pre-clinical stage, and seven are in discovery stage.

SM04646 is under Phase I stage of development by Samumed, LLC for the treatment of IPF. The drug candidate is a small molecule that acts as Wnt pathway modulator. Samumed is using the technology for development of small molecule that modulate Wnt pathway. The technology is not a stem cell therapy, instead focusing on the modulation of the Wnt pathway that recovers and restores the health of diseased tissues and presents significant opportunities in regenerative therapeutics.

Several companies are involved in IPF with their products in different phases. The only Phase III IPF drug candidate is being developed by Asahi Kasei Pharma Corporation. The IPF pipeline drug candidates of Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG and FibroGen, Inc. are in Phase II stage of development. Bristol-Myers Squibb Company is also having its IPF pipeline drug candidates in different clinical stages, including two drugs in Phase II and one drug in Phase I.


Some of the key players developing drug candidates for the treatment of IPF are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Global Blood Therapeutics, Inc., Asahi Kasei Corporation, Beijing Tide Pharmaceutical Co., Limited, FibroGen, Inc., Chong Kun Dang Pharmaceutical Corp., Galapagos NV, Kadmon Holdings, Inc., MediciNova, Inc., and Promedior, Inc.

Key Topics Covered:

1. Research Scope And Methodology

2. Executive Summary

3. Pipeline Outlook

4. Global Idiopathic Pulmonary Fibrosis (Ipf) Pipeline Analysis By Phase (2016)

5. Swot Analysis Of Idiopathic Pulmonary Fibrosis Pipeline

6. Company Profiles And Strategic Developments

7. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/xf6xx2/global_idiopathic

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-idiopathic-pulmonary-fibrosis-ipf-pipeline-analysis-2016-2017-ipf-pipeline-is-very-strong-with-a-total-of-97-drug-candidates---research-and-markets-300429005.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2019)... ... January 08, 2019 , ... ... designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Jaeger ... and demonstrated a commitment to exemplary care for men suffering from symptoms associated ...
(Date:1/8/2019)... ... January 08, 2019 , ... “A baby ... minutes. We can change that alarming statistic,” said Christina Chambers, PhD, MPH, President ... (OTIS). MotherToBaby is joining with leading prenatal health experts from the National Birth ...
(Date:1/7/2019)... (PRWEB) , ... January 07, 2019 , ... uBiome, the ... provides insights to help individuals understand how their gut microbes offer support in metabolizing ... role in how long the toxic byproducts of breakdown linger in your body. The ...
Breaking Medicine Technology:
(Date:1/15/2019)... ... January 15, 2019 , ... Ophthalmic Consultants of Long ... office to a new, larger space at 70 East Sunrise Highway, Suite 400, Valley ... needs of its patients. , According to Gerard D’Aversa, MD, “After serving the Valley ...
(Date:1/14/2019)... ... ... Yes, the Millennials love their Bluetooth earbuds and Alexa smart speakers. But according ... is also finding a home in senior living communities. , The 2018 Active-Aging ... organizations that work with older adults about their adoption of technology over a time ...
(Date:1/14/2019)... (PRWEB) , ... January 14, 2019 , ... ... to the use and availability of VARIZIG® (Varicella Zoster Immune Globulin [Human]) ... ( https://bit.ly/2M1l0UR ). In the update, the CDC notes that VARIZIG is commercially ...
(Date:1/14/2019)... ... January 14, 2019 , ... Specialty Technical ... updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Great Britain ... the scope of their EHS regulatory obligations and rapidly collect, share, archive, and ...
(Date:1/13/2019)... ... , ... Dr. Christine Kaczmar, a functional medicine doctor in Michigan, has created ... Model Is Creating More Sickness And Why Timeless Healing Principles Are Needed Now". ... Christine explains that judging our health by how we feel rather than how we ...
Breaking Medicine News(10 mins):